Company Information

Company Name

Lupagen

Company Description

Lupagen is the only integrated extracorporeal in-vivo gene therapy company • Founded in 2017 to make cell & gene therapy safer, more effective and broadly accessible • Preclinical device completed and FDA feedback on combination product confirmed • FIH study est. 2024 CAR T-cell therapy in oncology – FDA Interact Feb 2023 Broad, Flexible & Versatile Delivery Platform • Ability to target PBMC subsets (T-cells, NK-cells, macrophages, B cells, HSCs) • Delivery of multiple payloads possible (DNA, RNA or gene editing systems) • Can accommodate viral or non-viral delivery vehicles (LNP, PNP or EVs) Unique Investment Opportunity in revenue generating In Vivo Gene Therapy platform. • Est. sales $20-40M (5 yrs)/$200-300 M (>8 yrs) • Seeking growth capital round ($20 M) to accelerate development and expand capabilities to support additional customer growth •Expanded customer base revenues eliminates need for future rounds

Website

http://www.lupagen.com

Industry Type

BioTherapy

Incoming Channel

—